PMC:7441788 / 17774-17980
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T102 | 197-205 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T104 | 197-205 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T133 | 0-206 | Sentence | denotes | HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
644 | 166-174 | Species | denotes | patients | Tax:9606 |
672 | 0-3 | Chemical | denotes | HCQ | MESH:D006886 |
673 | 106-109 | Chemical | denotes | HCQ | MESH:D006886 |
711 | 197-205 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T118 | 73-80 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
T119 | 97-104 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T95 | 197-205 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
644 | 166-174 | Species | denotes | patients | Tax:9606 |
672 | 0-3 | Chemical | denotes | HCQ | MESH:D006886 |
673 | 106-109 | Chemical | denotes | HCQ | MESH:D006886 |
711 | 197-205 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T133 | 0-206 | Sentence | denotes | HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. |